Saturday, September 5, 2026

NVIDIA Launches 10+ Products at GTC Taipei: Vera CPU, DGX Station, and Cosmos 3 Target Enterprise AI Expansion

NVIDIA unveiled more than 10 products and partnerships at GTC Taipei, spanning edge AI, data center, robotics, and autonomous vehicles. The lineup includes the Vera CPU, DGX Station for Windows, RTX Spark PCs, Cosmos 3, and a new Agent Toolkit. All major ODM partners—Foxconn, Quanta, Super Micro, and others—are positioned to fulfill demand.

LM Salvado

June 7, 2026

NVIDIA Launches 10+ Products at GTC Taipei: Vera CPU, DGX Station, and Cosmos 3 Target Enterprise AI Expansion
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

NVIDIA announced more than 10 products at GTC Taipei, targeting every layer of enterprise AI from the desktop to the data center.1

The Vera CPU anchors the compute stack. Its predecessor, the Grace CPU, reached nearly 2.5 million shipments, establishing a proven supply chain for Vera's ramp.1 RTX Spark PCs are slated for Fall 2026 availability across major OEMs, creating a near-term hardware refresh cycle for enterprise buyers.1

DGX Station for Windows extends NVIDIA's data center brand to office environments. The move expands the addressable market beyond large-scale infrastructure to deskside deployments—a segment previously underserved by high-end AI hardware.1

Cosmos 3 and the Agent Toolkit round out the software layer. Together, they target generative simulation and agentic enterprise workflows, areas where NVIDIA is competing for developer mindshare alongside its hardware plays.1

The ODM ecosystem backing the launch is dense. Foxconn, Quanta, Wistron, Wiwynn, Pegatron, GIGABYTE, Compal, ASUS, and Super Micro are all established NVIDIA partners.1 That breadth reduces supply risk and accelerates time-to-market for new form factors like RTX Spark.

Analysts tracking the hardware cycle are watching Dell, HPE, Lenovo, and Super Micro for signals in their Q3 and Q4 2026 revenue guidance.1 Vera CPU shipment volumes relative to Grace's ramp trajectory will be a key benchmark for how quickly enterprise demand converts to revenue.

The multi-product blitz follows a familiar NVIDIA pattern: anchor a platform transition with silicon, extend it through software, and distribute through an entrenched ODM network. The scope of GTC Taipei—CPU, edge AI, data center, robotics, autonomous vehicles—signals that NVIDIA is positioning this cycle as a full-stack platform shift, not a point upgrade.1

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com